Thrombin generation as a predictor of outcomes in patients with non-traumatic intracerebral hemorrhage.

Front Neurol

Division of Clinical Laboratory Sciences, Department of Laboratory Medicine, Faculty of Medicine, Kálmán Laki Doctoral School, University of Debrecen, Debrecen, Hungary.

Published: August 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Non-traumatic intracerebral hemorrhage (ICH) accounts for 10-15% of all strokes and leads to a higher rate of mortality as compared to ischemic strokes. We aimed to find out whether the thrombin generation assay (TGA) could predict outcomes in patients with ICH.

Patients And Methods: In this prospective, observational study, 87 consecutive patients with ICH and 164 healthy controls were included. Computed tomography (CT), detailed clinical investigation, and laboratory investigations were performed from patients on admission. TGA was performed using stored platelet poor plasma obtained on admission. Lag time, endogen thrombin potential (ETP), peak thrombin, and time to peak parameters were calculated. Short- and long-term outcomes of ICH were defined at 14 days and 3 months post-event according to the NIHSS and the modified Rankin Scale (mRS), respectively.

Results: Peak thrombin was significantly higher in patients as compared to controls (397.2 ± 93.9 vs. 306 ± 85.3 nM, < 0.0001). Lag time, ETP, and time to peak parameters showed a significant positive correlation with CRP in both groups. In patients with worse long-term functional outcomes, peak thrombin was significantly higher as compared to those with favorable outcomes [mRS 2-6 median: 402.5 (IQR:344.8-473.8) vs. mRS 0-1: 326.4 (294.2-416.1) nM, = 0.0096]. Based on the statistically optimal threshold of 339.1 nM peak thrombin, the sensitivity and specificity of this parameter to determine mRS 2-6 as an outcome were 80.8 and 64.7%, respectively. In a binary logistic regression model including age, sex, BMI, smoking status, NIHSS on admission, D-dimer, and peak thrombin (>339.1 nM), only NIHSS and the peak thrombin parameters remained in the model as significant, independent predictors of poor outcome. Lag time and time to peak showed a modest, significant negative correlation with intracerebral bleeding volume on admission ( = -0.2603, = 0.0231 and = -0.3698, = 0.0010, respectively). During the follow-up of patients, estimated hemorrhage volumes on day 90 showed significant positive association with the ETP and peak thrombin parameters ( = 0.3838, = 0.0363 and = 0.5383, = 0.0021, respectively).

Conclusion: In patients with ICH, TG was increased as compared to healthy controls, which might be explained by the presence of higher inflammatory parameters in patients. Peak thrombin measured on admission might be a useful tool to predict outcomes in patients with ICH.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436391PMC
http://dx.doi.org/10.3389/fneur.2022.912664DOI Listing

Publication Analysis

Top Keywords

peak thrombin
32
outcomes patients
12
patients ich
12
lag time
12
time peak
12
thrombin
11
peak
11
patients
10
thrombin generation
8
non-traumatic intracerebral
8

Similar Publications

Background: Inherited thrombophilia (IT) is a genetically determined predisposition to thromboembolic events. Beyond the well-known G20210A mutation, there has been limited research on other prothrombin mutations in the Chinese population.

Objectives: This study aimed to identify and characterize a novel prothrombin mutation in a Han Chinese family with IT.

View Article and Find Full Text PDF

Background: Scarce data are available on pharmacodynamic (PD) variability in very elderly patients receiving direct oral anticoagulants (DOACs) for atrial fibrillation (AF). Thrombodynamics-4D (TD-4D), which simultaneously assesses fibrin clot formation and thrombin generation, has not yet been tested in patients on rivaroxaban, apixaban, or dabigatran.

Objectives: To (i) evaluate TD-4D's ability to assess DOAC effect added to normal plasma; (ii) assess DOAC PD in very elderly patients with AF along with DOAC concentrations; (iii) identify factors associated with interindividual variability of DOAC PD at peak and trough levels.

View Article and Find Full Text PDF

Plasma levels of tissue factor pathway inhibitor (TFPI) are elevated in many patients with COVID-19 but the role of TFPI in COVID-19 coagulopathy remains elusive. We sought to determine the contribution of TFPI to thrombin generation in patients with COVID-19 and assess its association with thrombosis and other clinical outcomes. We used blood samples from an early COVID-19 clinical trial of adult patients hospitalized with acute COVID-19 from April 2020 to January 2021 (ClinicalTrials.

View Article and Find Full Text PDF

Platelet derived prothrombotic microparticles (MP) have been associated with hemocompatibility related adverse events in patients with continuous flow left ventricular assist devices; little is known with the contemporary Impella platform micro-axial flow pumps. Indeed, the extended duration of support provided by the Impella 5.5 calls for a specific evaluation.

View Article and Find Full Text PDF

Background: Venous thromboembolism is a common cause of morbidity and mortality in patients with cancer, with chemotherapy being an established risk factor. Emerging data suggest elevated venous thromboembolism risk with immune checkpoint inhibitors (ICIs), yet the association between ICIs and hypercoagulability remains unclear.

Objectives: We aimed to evaluate longitudinal levels of hemostatic biomarkers in patients during chemotherapy and ICI monotherapy.

View Article and Find Full Text PDF